Has subject area
-
For 2008 6 Digit Code
-
Seo 2008 6 Digit Code
PROF Helmut Butzkueven
Positions
- Honorary, Medicine - Royal Melbourne Hospital
- Genetics
- Glial Biology
- Multipel Sclerosis Registries
- Multiple Sclerosis
Overview
Affiliation
Member of
- Society for Neuroscience. Member 2005 -
- Australian Neuroscience Society. Member 2004 -
- Australian Association of Neurologists. Member 2000 -
- American Association of Neurologists. Member 1999 -
Publications
Selected publications
2019
Journal Articles
- Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2019
- Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Multiple Sclerosis and Related Disorders. 28. 2019
- Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial. The Lancet Neurology. 2019
- Multiple sclerosis registries in Europe – An updated mapping survey. Multiple Sclerosis and Related Disorders. 27. 2019
- Prognosticating autoimmune encephalitis: A systematic review. Journal of Autoimmunity. 96. 2019
Journal Articles Refereed
- Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA: Journal of the American Medical Association. 321. 2019
- Validation of a precision tremor measurement system for multiple sclerosis. Journal of Neuroscience Methods. 311. 2019
2018
Journal Articles
- International consensus on quality standards for brain health-focused care in multiple sclerosis. Multiple Sclerosis. 2018
Journal Articles Refereed
- Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs. 32. 2018
- Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs. 32. 2018
- Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurology. 75. 2018
- Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis. Multiple Sclerosis. 24. 2018
- Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. European Radiology. 28. 2018
- Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study. Molecular Medicine. 24. 2018
- Dysequilibrium of the PTH-FGF23-vitamin D axis in relapsing remitting multiple sclerosis; a longitudinal study.. Molecular Medicine. 24. 2018
- Genotype and Phenotype in Multiple Sclerosis-Potential for Disease Course Prediction? 2018
- Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study. Multiple Sclerosis. 24. 2018
- Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple Sclerosis. 24. 2018
- Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis and Related Disorders. 19. 2018
- Monitoring cognitive change in multiple sclerosis using a computerized cognitive battery. 2018
- Multimodal characterization of gray matter alterations in neuromyelitis optica. Multiple Sclerosis. 24. 2018
- Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting. Multiple Sclerosis and Related Disorders. 24. 2018
- Novel Functional MRI Task for Studying the Neural Correlates of Upper Limb Tremor. Frontiers in Neurology. 9. 2018
- Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. Journal of the Neurological Sciences. 391. 2018
- Silent lesions on MRI imaging - Shifting goal posts for treatment decisions in multiple sclerosis. Multiple Sclerosis. 24. 2018
- Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod: Incidence, Prevalence, and Impact on Disease Course. Ophthalmology. 2018
- Vitamin D for the treatment of multiple sclerosis: a meta-analysis. Journal of Neurology. 265. 2018
- What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis. Autoimmunity Reviews. 17. 2018
Journal Articles Unrefereed Letters or Notes
- Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" Mult. Scler. Relat. Disord. (2017). Multiple Sclerosis and Related Disorders. 22. 2018
Other Refereed Contribution to Refereed Journals
- Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure. Therapeutic Advances in Neurological Disorders. 11. 2018
- Prognosis in autoimmune encephalitis: Database. Data in Brief. 21. 2018
2017
Journal Articles
- Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: A systematic review. Autoimmunity Reviews. 16. 2017
Journal Articles Refereed
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology. 89. 2017
- Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis. 23. 2017
- Data quality evaluation for observational multiple sclerosis registries. Multiple Sclerosis. 23. 2017
- Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 88. 2017
- Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology, Neurosurgery and Psychiatry. 88. 2017
- Interleukin-2 receptor-alpha proximal promoter hypomethylation is associated with multiple sclerosis. Genes and Immunity. 18. 2017
- Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies. British Journal of Pharmacology. 174. 2017
- Prognostic Indicators in Pediatric Clinically Isolated Syndrome. Annals of Neurology. 81. 2017
- Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice. Multiple Sclerosis. 23. 2017
- Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. The Lancet Neurology. 16. 2017
- Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. 140. 2017
- Treatment decisions in multiple sclerosis - insights from real-world observational studies. Nature Reviews Neurology. 13. 2017
- Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. The Lancet Neurology. 16. 2017
- Tremor in multiple sclerosis is associated with cerebello-thalamic pathology. Journal of Neural Transmission. 124. 2017
Conference Proceedings
2016
Journal Articles Refereed
- A genetic basis for multiple sclerosis severity: Red herring or real?. Molecular and Cellular Probes. 30. 2016
- Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve. 2016
- Brain health: time matters in multiple sclerosis. Multiple Sclerosis and Related Disorders. 9. 2016
- Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status. PLoS Genetics. 12. 2016
- Common and Low Frequency Variants in MERTK Are Independently Associated with Multiple Sclerosis Susceptibility with Discordant Association Dependent upon HLA-DRB1*15:01 Status. PLoS One. 11. 2016
- Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS. Neurology: Clinical Practice. 6. 2016
- Defining secondary progressive multiple sclerosis. Brain. 139. 2016
- Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study. Journal of Neurology, Neurosurgery and Psychiatry. 87. 2016
- Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP). PLoS One. 11. 2016
- Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 87. 2016
- Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2016
- Observational data: Understanding the real MS world. Multiple Sclerosis. 22. 2016
- Predictors of Long-Term Disability Accrual in Relapse-Onset Multiple Sclerosis. Annals of Neurology. 80. 2016
- Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis. European Journal of Neurology. 23. 2016
- Serial Diffusion Tensor Imaging of the Optic Radiations after Acute Optic Neuritis. Journal of Ophthalmology. 2016
- The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis. Multiple Sclerosis. 22. 2016
Journal Articles Unrefereed Letters or Notes
- Is my MS patient failing treatment?. Neurology. 87. 2016
- The importance of collecting structured clinical information on multiple sclerosis. BMC Medicine. 14. 2016
Conference Proceedings
- Anti-inflammatory disease modifying treatment does not attenuate disability progression in secondary progressive multiple sclerosis. Multiple Sclerosis. 2016
- Comparison of 5-year treatment outcomes between alemtuzumab versus natalizumab, fingolimod and interferon beta-1a. Multiple Sclerosis. 2016
- Comparison of MS outcomes after Switching to Natalizumab versus staying on Interferon-beta or glatiramer. Multiple Sclerosis. 2016
- Cumulative data on pregnancy outcomes after exposure to fingolimod and in comparison with the general population. Multiple Sclerosis. 2016
- Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod. Multiple Sclerosis. 2016
- MSBase: studies to date and future prospects.. Multiple Sclerosis. 2016
- Pregnancy protects against long-term disability accrual in relapsing-remitting MS. Multiple Sclerosis. 2016
- Progression to disability milestones in multiple sclerosis with long-term natalizumab treatment. Multiple Sclerosis. 2016
2015
Journal Articles Refereed
- A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data. Journal of Visualized Experiments. 2015
- A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. Human Molecular Genetics. 24. 2015
- Altered thalamic functional connectivity in multiple sclerosis. European Journal of Radiology. 84. 2015
- Association of plasma levels of Protein S with disease severity in multiple sclerosis. 2015
- BREMSO: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology. 22. 2015
- Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis. Multiple Sclerosis. 21. 2015
- Comparative efficacy of switching to natalizumab in active multiple sclerosis. Annals of Clinical and Translational Neurology. 2. 2015
- Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis. JAMA Neurology. 72. 2015
- Defining reliable disability outcomes in multiple sclerosis. Brain. 138. 2015
- Galanin is an Autocrine Myelin and Oligodendrocyte Trophic Signal Induced by Leukemia Inhibitory Factor. Glia. 63. 2015
- Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. PLoS One. 10. 2015
- Multiple sclerosis in Latin America: A different disease course severity? A collaborative study from the MSBase Registry. 2015
- Parallel Changes in Structural and Functional Measures of Optic Nerve Myelination after Optic Neuritis. PLoS One. 10. 2015
- Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis. Annals of Neurology. 77. 2015
- Switching from natalizumab to fingolimod A randomized, placebo-controlled study in RRMS. Neurology. 85. 2015
- The MS Risk Allele of CD40 Is Associated with Reduced Cell-Membrane Bound Expression in Antigen Presenting Cells: Implications for Gene Function. PLoS One. 10. 2015
- The occurrence of dystonia in upper-limb multiple sclerosis tremor. Multiple Sclerosis. 21. 2015
Other Refereed Contribution to Refereed Journals
- A new era in the treatment of multiple sclerosis. Medical Journal of Australia. 203. 2015
2014
Journal Articles Refereed
- Axonally derived matrilin-2 induces proinflammatory responses that exacerbate autoimmune neuroinflammation. Journal of Clinical Investigation. 124. 2014
- Ceruloplasmin gene-deficient mice with experimental autoimmune encephalomyelitis show attenuated early disease evolution. Journal of Neuroscience Research. 92. 2014
- Cortical Thinning Correlates with Cognitive Change in Multiple Sclerosis but not in Neuromyelitis Optica. European Radiology. 24. 2014
- Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. Journal of Neurology & Neurophysiology. Feb 14 2014. 2014
- Fingolimod after natalizumab and the risk of short term relapse. Neurology. 82. 2014
- Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Multiple Sclerosis. 20. 2014
- Risk of relapse phenotype recurrence in multiple sclerosis. Multiple Sclerosis. 20. 2014
- Seasonal Variation of Relapse Rate in Multiple Sclerosis is Latitude Dependent. Annals of Neurology. 76. 2014
- Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients. Journal of Neurology, Neurosurgery and Psychiatry. 17 March 2014. 2014
- Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies. Journal of Clinical Neuroscience. 21. 2014
- Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy. Journal of Clinical Neuroscience. 21. 2014
- Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations. Journal of Clinical Neuroscience. 21. 2014
- Time for change - Evolution of real-world evidence outcome measures in multiple sclerosis exemplified by fingolimod 2014
Other Refereed Contribution to Refereed Journals
- Clinical/scientific notes. Neurology(R) neuroimmunology & neuroinflammation. 1. 2014
Conference Proceedings
- Patients who switch to natalizumab have better outcomes than those who continue on the same platform therapy after a relapse. European Journal of Neurology. 2014
- Patients who switch to natalizumab have better outcomes than those who continue on the same platform therapy after a relapse. Journal of Neurology. 2014
2013
Book Chapters Other
- Genetic predisposition: humans. The Autoimmune Diseases. Academic Press. 2013
Journal Articles Refereed
- Amine oxidase activity of beta-amyloid precursor protein modulates systemic and local catecholamine levels. Molecular Psychiatry. 18. 2013
- Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nature Genetics. 45. 2013
- Anti-aquaporin-4 antibody positivity in neuromyelitis optica is associated with lesion activity. European Neurology. 70. 2013
- Endogenously regulated Dab2 worsens inflammatory injury in experimental autoimmune encephalomyelitis. ACTA Neuropathologica Communications. 1. 2013
- EphA4 Receptor Tyrosine Kinase Is a Modulator of Onset and Disease Severity of Experimental Autoimmune Encephalomyelitis (EAE). PLoS One. 8. 2013
- Estimation and partitioning of polygenic variation captured by common SNPs for Alzheimer's disease, multiple sclerosis and endometriosis. Human Molecular Genetics. 22. 2013
- Fluctuations of MS births and UV-light exposure. Acta Neurologica Scandinavica. 127. 2013
- Health-related quality of life as an independent predictor of long-term disability for patients with relapsing–remitting multiple sclerosis. European Journal of Neurology. 20. 2013
- Microstructural abnormalities in the trigeminal nerves of patients with trigeminal neuralgia revealed by multiple diffusion metrics. European Journal of Radiology. 82. 2013
- Optic Nerve Diffusion Tensor Imaging after Acute Optic Neuritis Predicts Axonal and Visual Outcomes. PLoS One. 8. 2013
- Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis. PLoS One. 8. 2013
- Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to disability change: a longitudinal study. Health and Quality of Life Outcomes. 11. 2013
- Sex as a determinant of relapse incidence and progressive course of multiple sclerosis. Brain. 136. 2013
- The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective, Multicentre Study of Drug Utilisation Using the MSBase Platform. PLoS One. 8. 2013
- The CYP27B1 variant associated with an increased risk of autoimmune disease is underexpressed in tolerizing dendritic cells. Human Molecular Genetics. 23. 2013
Journal Articles Unrefereed Letters or Notes
- Aspergillus arachnoiditis post intrathecal baclofen pump insertion. Journal of Clinical Neuroscience. 20. 2013
- Commentary on "possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection". Journal of Clinical Neuroscience. 20. 2013
Conference Proceedings
- Comparison of Patients Treated with Natalizumab and Interferon-beta/Glatiramer Using Propensity-Matched Multiple Sclerosis Registry Data. Neurology. 2013
- Cumulative data on pregnancy outcomes after exposure to fingolimod. Multiple Sclerosis. 2013
- Disease activity and disability progression decrease beyond two years on natalizumab in relapsing multiple sclerosis patients in the TYSABRI (R) (natalizumab) Observational Programme. Multiple Sclerosis. 2013
- Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO). Multiple Sclerosis. 2013
- Effect of LINGO-1 Blockade on Optic Nerve Axonal Injury in MOG-EAE Rodent Models. Neurology. 2013
- Fingolimod Observational Studies Program in Patients with Relapsing Multiple Sclerosis: Study Designs. Neurology. 2013
- INVESTIGATING THE INFLUENCE OF LIF-RECEPTOR SIGNALING UPON NEURAL PRECURSORS AND OLIGODENDROGLIA AS A MODULATOR OF DEMYELINATING DISEASE. Glia. 2013
- Multinational Gilenya (TM) (Fingolimod) Pregnancy Exposure Registry: Preliminary Results. Neurology. 2013
- Predictors of 12 Month Confirmed Disability Progression after Onset of Clinically Isolated Syndrome (CIS) Suggestive of Multiple Sclerosis. Neurology. 2013
- ROLE OF THE beta 2 ADRENERGIC RECEPTOR IN MULTIPLE SCLEROSIS SEVERITY. Glia. 2013
2012
Journal Articles Refereed
- A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor. Neurology. 79. 2012
- A tract-based diffusion study of cerebral white matter in neuromyelitis optica reveals widespread pathological alterations. Multiple Sclerosis. 18. 2012
- Altered Topological Organization of White Matter Structural Networks in Patients with Neuromyelitis Optica. PLoS One. 7. 2012
- Baseline brain activity changes in patients with clinically isolated syndrome revealed by resting-state functional MRI. Acta Radiologica. 53. 2012
- Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. PLoS One. 7. 2012
- Diffusion tensor imaging correlates of visual impairment in multiple sclerosis and chronic optic neuritis. Investigative Ophthalmology and Visual Science. 53. 2012
- Diffusion tensor imaging correlates of visual impairment in multiple sclerosis and chronic optic neuritis.. Investigative Ophthalmology and Visual Science. 21. 2012
- Diffusion tensor imaging of acute inflammatory lesion evolution in multiple sclerosis. Journal of Clinical Neuroscience. 19. 2012
- Diffusion tensor imaging of the optic radiations after optic neuritis. Human Brain Mapping. 33. 2012
- Geographical Variations in Sex Ratio Trends over Time in Multiple Sclerosis. PLoS One. 7. 2012
- Increasing age at disability milestones among MS patients in the MSBase Registry. Journal of the Neurological Sciences. 318. 2012
- Interleukin-6 Gene Promoter-572 C Allele May Play a Role in Rate of Disease Progression in Multiple Sclerosis. International Journal of Molecular Sciences. 13. 2012
- Leukemia inhibitory factor protects axons in experimental autoimmune encephalomyelitis via an oligodendrocyte-independent mechanism. PLoS One. 7. 2012
- Optic Nerve Magnetisation Transfer Ratio after Acute Optic Neuritis Predicts Axonal and Visual Outcomes. PLoS One. 7. 2012
- The Kurtzke EDSS rank stability increases 4 years after onset of Multiple Sclerosis: results from the MSBase Registry. Journal of Neurology, Neurosurgery and Psychiatry. 83. 2012
- The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Multiple Sclerosis. 18. 2012
- What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?. International Journal of Molecular Sciences. 13. 2012
Other Refereed Contribution to Refereed Journals
- Closing the case of APOE in multiple sclerosis: No association with disease risk in over 29 000 subjects. Journal of Medical Genetics. 49. 2012
Conference Proceedings
- Altered topological organisation of white matter structural networks in patients with neuromyelitis optica. Multiple Sclerosis. 2012
- Assessment of Baseline Characteristics, Treatment Efficacy, and Serious Adverse Events among Natalizumab-Treated MS Patients without Prior Treatment. Neurology. 2012
- BIIB033 Anti-LINGO-1 antibody reduces optic nerve axonal degeneration in MOG- EAE rodent models. Multiple Sclerosis. 2012
- Baseline axial diffusivity predicts poor visual recovery at 6 months after acute optic neuritis. Multiple Sclerosis. 2012
- Baseline characteristics, treatment efficacy, and serious adverse events in natalizumab-treated MS patients without prior treatment. Journal of Neurology. 2012
- Correlation between structural and functional measures of optic nerve myelination. Multiple Sclerosis. 2012
- EXPOSURE TO INTERFERON-beta THERAPY IN EARLY PREGNANCY: A LITERATURE REVIEW OF PREGNANCY OUTCOMES IN WOMEN WITH MULTIPLE SCLEROSIS. Journal of Neurology, Neurosurgery and Psychiatry. 2012
- Endogenous leukaemia inhibitory factor signalling reduces axonal damage in mice with EAE. Multiple Sclerosis. 2012
- Long-Term Safety and Efficacy and Association between Baseline Treatment History and Postbaseline Relapses in Multiple Sclerosis Patients Treated with Natalizumab in the TYSABRI (R) Observational Program (TOP). Neurology. 2012
- Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI(R) observational programme. Multiple Sclerosis. 2012
- Longitudinal changes in normal appearing white matter in isolated optic neuritis patients suggestive of MS. Multiple Sclerosis. 2012
- Matrilin-2 expression is up-regulated in murine Experimental Autoimmune Encephalomyelitis (EAE) and human Multiple Sclerosis lesions. Multiple Sclerosis. 2012
- Multinational Gilenya (TM) (Fingolimod) Pregnancy Exposure Registry in Multiple Sclerosis: Study Design. Neurology. 2012
- Optic nerve MTR at 3 months reflect RNFL thinning 12 months after onset of optic neuritis. Multiple Sclerosis. 2012
- PREDICTORS OF POSTPARTUM RELAPSES IN WOMEN WITH MULTIPLE SCLEROSIS: RESULTS FROM THE MSBASE REGISTRY. Journal of Neurology, Neurosurgery and Psychiatry. 2012
- Pharmacogenomics of interferon beta and glatiramer acetate response in Australian MS Patients. Multiple Sclerosis. 2012
- Predictors of time to first confirmed disability progression after clinically isolated syndrome onset: an MSBase study. Multiple Sclerosis. 2012
- Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya (TM) (fingolimod) Pregnancy Exposure Registry in multiple sclerosis. Multiple Sclerosis. 2012
- The CogState Brief Battery (CBB): clinical advantages in detecting early cognitive impairment in patients with multiple sclerosis (preliminary data). Multiple Sclerosis. 2012
- The Temporal Profile of Optic Nerve MTR Values in the First Year After Acute Optic Neuritis. Multiple Sclerosis. 2012
- The temporal profile of optic nerve DTI measures and RNFL thickness in the first year after acute optic neuritis. Multiple Sclerosis. 2012
- Treatment persistence in the Australian relapsing remitting MS population: Results from the MSBase Registry. Multiple Sclerosis. 2012
- Tysabri (R) Observational Program (TOP) results: long-term safety and efficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treated with natalizumab. Journal of Neurology. 2012
Conference Papers Unrefereed
2011
Journal Articles
- Neurodegeneration in MS and NMO: The Eye and the Blood.. Multiple Sclerosis International. 2011. 2011
Journal Articles Refereed
- A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology. 77. 2011
- A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis . Neurology. 77. 2011
- Brain plasticity in relapsing-remitting multiple sclerosis: Evidence from resting-state fMRI. Journal of the Neurological Sciences. 304. 2011
- Clinical isolated syndrome: A 3-year follow-up study in China. Clinical Neurology and Neurosurgery. 113. 2011
- Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. The Lancet Neurology. 10. 2011
- Familial recurrence risks for multiple sclerosis in Australia. Journal of Neurology, Neurosurgery and Psychiatry. 82. 2011
- Genomewide meta-analysis identifies novel multiple sclerosis susceptibility loci.. Annals of Neurology. 70. 2011
- Heterogeneity at the HLA-DRB1 allelic variation locus does not influence multiple sclerosis disease severity, brain atrophy or cognition. Multiple Sclerosis. 17. 2011
- Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Medicine: medicine in the post-genomic era. 3. 2011
- Neurofilament Proteins as Body Fluid Biomarkers of Neurodegeneration in Multiple Sclerosis. Multiple Sclerosis International. 2011. 2011
- The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. European Journal of Neurology. 18. 2011
- Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in mice. PLoS One. 6. 2011
Journal Articles Unrefereed Letters or Notes
Conference Proceedings
- Design of the RECORD MS study and pregnancy registry in patients with multiple sclerosis receiving cladribine tablets therapy in normal medical care. Journal of Neurology. 2011
- RELATIONSHIP BETWEEN BASELINE TREATMENT HISTORY AND POSTBASELINE RELAPSES AND SERIOUS ADVERSE EVENTS IN NATALIZUMAB-TREATED PATIENTS WITH MULTIPLE SCLEROSIS (MS): TYSABRI (R) OBSERVATIONAL PROGRAM (TOP). European Journal of Neurology. 2011
- Relationship between baseline treatment history and post-baseline relapses and serious adverse events in natalizumab-treated patients with multiple sclerosis. Journal of Neurology. 2011
Conference Papers Unrefereed
2010
Research Book Chapters
- Galanin in Glia: Expression and Potential Roles in the CNS. Experientia Supplementum: Galanin. Springer. 2010
Journal Articles Refereed
- A Polymorphism in the HLA-DPB1 Gene Is Associated with Susceptibility to Multiple Sclerosis. PLoS One. 5. 2010
- A Transcription Factor Map as Revealed by a Genome-Wide Gene Expression Analysis of Whole-Blood mRNA Transcriptome in Multiple Sclerosis. PLoS One. 5. 2010
- Common variation in the MOG gene influences transcript splicing in humans. Journal of Neuroimmunology. 229. 2010
- MicroRNAs miR-17 and miR-20a Inhibit T Cell Activation Genes and Are Under-Expressed in MS Whole Blood. PLoS One. 5. 2010
- Multiple Sclerosis Susceptibility-Associated SNPs Do Not Influence Disease Severity Measures in a Cohort of Australian MS Patients. PLoS One. 5. 2010
- Neuroprotection in multiple sclerosis: A therapeutic challenge for the next decade. Pharmacology and Therapeutics. 126. 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. New England Journal of Medicine. 362. 2010
- Saliva-Derived DNA Performs Well in Large-Scale, High-Density Single-Nucleotide Polymorphism Microarray Studies. Cancer Epidemiology, Biomarkers & Prevention. 19. 2010
- The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Human Molecular Genetics. 19. 2010
Conference Proceedings
- Benefits of the serum-free formulation of interferon beta-1a: Lessons from clinical trials. Multiple Sclerosis. 2010
- Long-term safety and impact of natalizumab on disease activity and disability progression in patients with relapsing-remitting MS in clinical practice: TYSABRI (R) Observational Program (TOP). Journal of Neurology. 2010
- Long-term safety and impact of natalizumab on disease activity and disability progression in patients with relapsing-remitting MS in clinical practice: TYSABRI (R) Observational Program (TOP). European Journal of Neurology. 2010
- Responsiveness of the Multiple Sclerosis International Quality of Life (MusiQOL) questionnaire to changes in disability in patients with multiple sclerosis: 12-month results. European Journal of Neurology. 2010
2009
Journal Articles
- Paraclinical Correlates of Visual Acuity Loss in Multiple Sclerosis. Journal of Clinical Neuroscience. 16. 2009
- Re: Early relapses after the first dose of natalizumab in active multiple sclerosis. Multiple Sclerosis. 15. 2009
Journal Articles Refereed
- A role for galanin in human and experimental inflammatory demyelination. Proceedings of the National Academy of Sciences of the United States of America. 106. 2009
- Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology. 73. 2009
- Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus. Journal of Neuroimmunology. 211. 2009
- Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20.. Nature Genetics. 41. 2009
- HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis.. Tissue Antigens. 74. 2009
- Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. Neuroimage. 45. 2009
- Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. Neuroimage. 45. 2009
Journal Articles Unrefereed Letters or Notes
- Early relapses after the first dose of natalizumab in active multiple sclerosis.. Multiple Sclerosis. 15. 2009
Other Refereed Contribution to Refereed Journals
- How to diagnose multiple sclerosis and what are the pitfalls. Internal Medicine Journal. 39. 2009
Conference Proceedings
- Baseline axial diffusivity is predictive of retinal nerve fibre layer thinning after acute optic neuritis. Multiple Sclerosis. 2009
- Early relapses after the first dose of natalizumab in active multiple sclerosis. Multiple Sclerosis. 2009
- Method for optic nerve intensity characterization in mice from Mn2+ enhanced MR images. Progress in Biomedical Optics and Imaging. 2009
- Modulation of regulatory and cytotoxic T cell expression signature in early multiple sclerosis. European Journal of Neurology. 2009
- Natalizumab observational programme: assessment of long-term safety and impact on disease activity and progression of natalizumab in patients with relapsing-remitting multiple sclerosis. Multiple Sclerosis. 2009
- Onset of relapses in multiple sclerosis: the effect of seasonal change in both the northern and southern hemisphere. Multiple Sclerosis. 2009
- SEASONAL VARIATION OF ONSET OF RELAPSES IN MULTIPLE SCLEROSISIN THE NORTHERN AND SOUTHERN HEMISPHERES: RESULTS FROM THE MSBASE REGISTRY. Journal of Neurology, Neurosurgery and Psychiatry. 2009
- TYSABRI (R) observational program: a long-term evaluation of safety and impact on disease activity and progression of natalizumab in relapsing-remitting MS. Journal of the Neurological Sciences. 2009
- Temporal variation of onset of relapses in multiple sclerosis is not seasonal: results from the MSBase registry. Multiple Sclerosis. 2009
- The HLA-DR2 genotype does not affect MS severity, cognition or brain atrophy. Multiple Sclerosis. 2009
- The Multiple Sclerosis Severity Score (MSSS) re-examined: EDSS rank stability in the MSBase dataset increases 5 years after onset of multiple sclerosis. Multiple Sclerosis. 2009
- The global MSBase registry: facilitating collaborative research. Multiple Sclerosis. 2009
2008
Journal Articles
- Reply to "Is there sentinel demyelination before development of primary CNS lymphoma?". Journal of Clinical Neuroscience. 15. 2008
Journal Articles Refereed
- Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF. Current Medical Research and Opinion. 24. 2008
- Gas6 deficiency increases oligodendrocyte loss and microglial activation in response to cuprizone-induced demyelination. Journal of Neuroscience. 28. 2008
- Genes implicated in multiple sclerosis pathogenesis from consilience of genotyping and expression profiles in relapse and remission.. BMC Medical Genetics. 9. 2008
- Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia. 56. 2008
- Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair . Glia. 56. 2008
- Measurement of disability in multiple sclerosis. Neurology Asia. 13. 2008
- Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians. Genes and Immunity. 9. 2008
- SNP mapping and candidate gene sequencing in the class I region of the HLA complex: searching for multiple sclerosis susceptibility genes in Tasmanians. Tissue Antigens. 71. 2008
- Validation of a Novel Biomarker for Acute Axonal Injury in Experimental Autoimmune Encephalomyelitis. Journal of Neuroscience Research. 86. 2008
- Validation of linear cerebral atrophy markers in multiple sclerosis. Journal of Clinical Neuroscience. 15. 2008
- Variants of ST8SIA1 are associated with risk of developing multiple sclerosis. PLoS One. 3. 2008
Conference Proceedings
- Apolipoprotein E4 genotype does not influence multiple sclerosis phenotype, severity, cognition or brain atrophy in a large Australian cohort. Multiple Sclerosis. 2008
- Gene expression profiling from T cells in patients with a first demyelinating episode. Multiple Sclerosis. 2008
- Magnetic resonance imaging quantification of lumbar spinal cord inflammation in mouse experimental autoimmune encephalomyelitis in vivo. Multiple Sclerosis. 2008
- Reduced diffusion anisotropy in optic radiation correlates with optic nerve atrophy after optic neuritis. Multiple Sclerosis. 2008
- The Multiple Sclerosis Severity Score re-examined: Expanded Disability Status Scale rank stability in the MSBase dataset increases five years after onset of multiple sclerosis. Multiple Sclerosis. 2008
- Time to regression from trial-defined disease progression in multiple sclerosis is dependent upon baseline Expanded Disablility Status Scale. Multiple Sclerosis. 2008
Patents
2007
Journal Articles Refereed
- Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patients. Immunogenetics. 59. 2007
- MR diffusion changes correlate with ultrastructurally defined axonal degeneration in murine optic nerve. Neuroimage. 37. 2007
- Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia.. Journal of Neurology. 254. 2007
Other Refereed Contribution to Refereed Journals
- Dopamine agonist-induced pathological gambling in restless legs syndrome due to multiple sclerosis. Movement Disorders. 22. 2007
- Prolonged interval between sentinel pseudotumoral demyelination and development of primary CNS lymphoma. Journal of Clinical Neuroscience. 14. 2007
Conference Proceedings
- Quantitative diffusion tensor imaging of the human optic nerve after severe unilateral optic neuritis. Multiple Sclerosis. 2007
2006
Journal Articles
- Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss. Glia. 53. 2006
- Oligodendrocytes exhibit selective expression of suppressor of cytokine signaling genes and signal transducer and activator of transcription 1 independent inhibition of interferon-gamma-induced toxicity in response to leukemia inhibitory factor. Neuroscience. 137. 2006
- On the utility of data from the International HapMap Project for Australian association studies. Human Genetics. 119. 2006
Journal Articles Refereed
- Endogenous Leukemia Inhibitory Factor Production Limits Autoimmune Demyelination and Oligodendrocyte Loss. Glia. 53. 2006
- Gait and balance impairment in early multiple sclerosis in the absence of clinical disability. Multiple Sclerosis. 12. 2006
- Oligodendrocytes exhibit selective expression of suppressor of cytokine signaling genes and signal transducer and activator of transcription 1 independent inhibition of interferon-gamma-induced toxicity in response to leukemia inhibitory factor.. Neuroscience. 137. 2006
- On the utility of data from the International HapMap Project for Australian association studies. Human Genetics. 119. 2006
- Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses.. Journal of Clinical Neuroscience. 13. 2006
- Suppressor of Cytokine Signaling 3 Limits Protection of Leukemia Inhibitory Factor Receptor Signaling against Central Demyelination. Proceedings of the National Academy of Sciences of the United States of America. 103. 2006
- Suppressor of cytokine signaling 3 limits protection of leukemia inhibitory factor receptor signaling against central demyelination.. Proceedings of the National Academy of Sciences of the United States of America. 103. 2006
Other Refereed Contribution to Refereed Journals
- MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Multiple Sclerosis. 12. 2006
Conference Proceedings
- Cerebellar dysfunction is associated with cognitive impairment in patients with multiple sclerosis. Multiple Sclerosis. 2006
- Developing strategies to manage neutralising antibodies - preliminary results from the RENeu study. Multiple Sclerosis. 2006
- Development of optic nerve diffusion weighted magnetic resonance imaging for translational research. Multiple Sclerosis. 2006
2005
Research Book Chapters
- Multiple sclerosis: a haplotype association study. Genetics of Autoimmunity: Novartis Foundation Symposium 267. John Wiley & Sons. 2005
- Multiple sclerosis: a hapoltype association study. The genetics of autoimmunity. Wiley-VCH. 2005
Journal Articles
Journal Articles Refereed
Journal Articles Unrefereed Letters or Notes
Conference Proceedings
- Haplotype mapping in the HLA complex implicates variation in the MOG gene in susceptibility to multiple sclerosis. Tissue Antigens. 2005
- The MSBase Global Web Registry: joining independent local patient databases for multi-centre research. Journal of the Neurological Sciences. 2005
2004
Journal Articles Refereed
- Extended haplotype analysis in the HLA complex reveals an increased frequency of the HFE-C282Y mutation in individuals with multiple sclerosis. Human Genetics. 114. 2004
- LIF receptor signaling modulates neural stem cell renewal. Molecular and Cellular Neurosciences. 27. 2004
- Neuroglial responses to CNS injury: prospects for novel therapeutics. Expert Review of Neurotherapeutics. 4. 2004
- Serial MRI in multiple sclerosis: a prospective pilot study of lesion load, whole brain volume and thalamic atrophy. Journal of Clinical Neuroscience. 11. 2004
Other Refereed Contribution to Refereed Journals
- Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis. Internal Medicine Journal. 34. 2004
Conference Proceedings
2003
Journal Articles Refereed
- Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. British Medical Journal. 327. 2003
- Schwann cell apoptosis in the postnatal axotomized sciatic nerve is mediated via NGF through the low-affinity neurotrophin receptor. Journal of Neuropathology and Experimental Neurology. 62. 2003
2002
Journal Articles Refereed
- Prospects for stem cell transplantation in multiple sclerosis. Journal of Clinical Neuroscience. 9. 2002
Conference Proceedings
- Genetic dissection of the HLA region using haplotypes of Tasmanians with multiple sclerosis. European Journal of Human Genetics. 2002
2001
Journal Articles
Journal Articles Refereed
- Neurotrophin receptor expression and responsiveness by postnatal cerebral oligodendroglia. NeuroReport. 12. 2001
2000
Journal Articles
- Immunosuppressive therapy is valuable in aggressive Multiple Sclerosis. Journal of Clinical Neuroscience. 7. 2000
- Nitrous oxide myelopathy in an abuser of whipped cream bulbs. Journal of Clinical Neuroscience. 7. 2000
- Onset seizures independently predict poor outcome after subarachnoid hemorrhage. Neurology. 55. 2000
- Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor. Journal of Neuroscience Research. 59. 2000
- Treatment of experimental autoimmune encephalomyelitis with antisense oligonucleotides against the low affinity neurotrophin receptor. Journal of Neuroscience Research. 59. 2000
1999
Journal Articles
- Combined peripheral nerve and central nervous system demyelination in a patient with chronic inflammatory demyelinating polyneuropathy. Journal of Clinical Neuroscience. 6. 1999
- Combined peripheral nerve and central nervous system demyelination in a patient with chronic inflammatory demyelinating polyneuropathy. Journal of Clinical Neuroscience. 6. 1999
1997
Journal Articles
- A case of serotonin syndrome induced by moclobemide during an extreme heatwave. Australian and New Zealand Journal of Medicine. 27. 1997
Research
Investigator on
-
Contract
- Genotype-Phenotype Correlations in Multiple Sclerosis administered by Medicine - Royal Melbourne Hospital 2014 -
- CELLULAR GENOMIC APPROACH TO THE PATHOGENESIS OF MULTIPLE SCLEROSIS (Linkage Projects) awarded by JAMES COOK UNIVERSITY 2011 - 2013
-
Grant
- CHARACTERIZING THE EFFECTS OF VITAMIN D SUPPLEMENTATION ON IMMUNE GENE EXPRESSION IN PATIENTS WITH A CLINICALLY ISOLATED SYNDROME (Incubator Grant) awarded by MULTIPLE SCLEROSIS RESEARCH AUSTRALIA LTD 2017 - 2018
- A Phase II Randomised Controlled Trial of An early Tailored Cognitive Behavioural Therapy Based Intervention for Depression in Those Newly Diagnosed with Multiple Sclerosis (ACTION-MS) (Project Grant) awarded by MULTIPLE SCLEROSIS RESEARCH AUSTRALIA LTD 2016 - 2019
- VISUALIZING BIOLOGICAL NETWORKS AND INFERRING INTERRELATIONSHIPS BETWEEN GENES AND THEIR PRODUCTS AS AN APPROACH TO UNDERSTANDING MULTIPLE SCLEROSIS (Project Grant) awarded by JAMES COOK UNIVERSITY 2016 - 2018
- TREATING PROGRESSIVE MULTIPLE SCLEROSIS (Project Grants) awarded by NHMRC 2015 - 2018
- Validation of protein expression changes associated with multiple sclerosis risk expression quantitative trait loci, in selected immune cell types (Incubator Grant) awarded by MULTIPLE SCLEROSIS RESEARCH AUSTRALIA LTD 2015
- INVESTIGATING FACTORS THAT LEAD TO MULTIPLE SCLEROSIS (Project Grants) awarded by NHMRC 2014 - 2016
- Genotype-Phenotype correlations in Multiple Sclerosis (Project Grant) awarded by MSBASE FOUNDATION 2014 - 2015
- Genetic markers of MS prognosis (Project Grant) awarded by CHARITYWORKS FOR MS 2013 - 2014
- Do MS risk SNPs influence alternative splicing in nearby genes? (Project Grant) awarded by CHARITYWORKS FOR MS 2013
- How do Multiple Sclerosis Risk genes work? (Project Grants) awarded by NHMRC 2012 - 2015
- Is MS treatment effective long-term? (Project Grants) awarded by NHMRC 2012 - 2014
- Does expression of regulator of g-protein signalling 1(RGS1), affect immune cell functionality? (Project Grant) awarded by CHARITYWORKS FOR MS 2012 - 2013
- Effect of treatment decisions on disease activity and disability progression in MS (Postdoctoral Fellowship) awarded by MULTIPLE SCLEROSIS RESEARCH AUSTRALIA LTD 2012 - 2013
- EPIGENETIC STUDY OF PERIPHERAL BLOOD LYMPHOCYTES IN MULTIPLE SCLEROSIS: ESTABLISHING PRINCIPLES TO DECONVOLUTE EPIGENETIC SIGNALS FROM DNA DERIVED FROM UNSORTED BLOOD LEUCOCYTES TO GIVE MEANING TO GWAS (Interdisciplinary Seed Grants) awarded by UNIVERSITY OF MELBOURNE 2012 -
- Understanding early changes in Multiple Sclerosis (Project Grants) awarded by NHMRC 2011 - 2014
- How do MS risk genes work in immune cells? (Neurology Research Grant) awarded by MERCK SERONO AUST PTY LTD 2011 - 2013
- CENTRE FOR TRANSLATIONAL NEUROSCIENCE: A MODULAR PLATFORM FOR TRANSLATING DISCOVERY INTO HEALTH OUTCOMES (Centres of Research Excellence) awarded by NHMRC 2010 - 2016
- Multiple Sclerosis: Investigating the cause and differences in outcome (Career Development Awards) awarded by NHMRC 2010 - 2013
- Testing paraclinical outcome measures in optic neuritis (Research grants) awarded by NATIONAL MULTIPLE SCLEROSIS SOCIETY 2010 - 2013
- Developing new blood tests for brain injury in multiple sclerosis patients. (Project Grants) awarded by NHMRC 2010 - 2012
- Protecting the nervous system from inflammation (Project Grants) awarded by NHMRC 2008 - 2010
- Neuroprotection in Multiple Sclerosis (Project Grants) awarded by NHMRC 2007 - 2009
- Investigating glial responses promoting remyelination and repair after demyelinating insults (Peter Doherty Fellowships) awarded by NHMRC 2006 - 2009
- GLAXOSMITHKLINE AUSTRALIA FELLOWSHIP IN NEUROLOGY (RACP Fellowship) awarded by ROYAL AUST COLLEGE OF PHYSICIANS 2006 - 2007
- IMPROVING MULTIPLE SCLEROSIS TREATMENT OUTCOMES (Practitioner Fellowship) awarded by NHMRC - 2018
- PREDICTING AND IMPROVING MULTIPLE SCLEROSIS TREATMENT OUTCOMES (Career Development Fellowships) awarded by NHMRC
Awards
Education and training
- PhD, University of Melbourne 2003
- MBBS, University of Melbourne 1992
Awards and honors
- Eureka Prize for Medical Research (for the MS Group), 2008
- RACP GSK Fellowship in Neurology, 2006
- Betty Cuthbert Fellowship NHMRC/MSRA, 2005
- Bethlehem Griffith Research Foundation Award for Medical Research, 2004
- Royal Melbourne Hospital Cleveland Prize for Medical Research, 2002
- Fellow of the Royal Australasian College of Physicians, 1999
- Novartis Medal for Medical Research, St Vincent's Hospital, Melbourne, 1998
Linkages
Geographic focus
Supervision
Available for supervision
- Y
- Contact Details
-
butz@unimelb.edu.au
-
61393427061
-
fax: 61393495997
-
Location
- Level: 04 Room:, Clinical Sciences, Royal Melbourne Hospital
-
- Graduate Study
-
- Interested in Graduate Study at Melbourne? Next steps:
-
-
Visualization Gallery
- Collaboration
- Research Area Visualizations
